Figure 3 | Cell Death & Disease

Figure 3

From: Primary hematopoietic cells from DBA patients with mutations in RPL11 and RPS19 genes exhibit distinct erythroid phenotype in vitro

Figure 3

Degree of apoptosis in the DBA patients during erythroid differentiation. (a) Percentage of Annexin-V-positive cells during terminal erythroid differentiation in DBA patients, who carried mutation in RPS19 (RPS19+/Mut) (n=2) (dark grey plot), in RPL11 (RPL11+/Mut) (n=3) (light gray plot) compared with the controls (n=8) (black plot). The differences were statistically significant between controls and RPS11+/Mut at days 7, 10 and 12 (P<0.001). Only two RPS19+/Mut samples were studied for Annexin-V and statistical significance was not studied. However, nine other samples were studied by the TUNEL assay. If we pool the results from these two techniques investigating apoptosis, a much less statistical difference has been observed between controls and the RPS19+/Mut samples (P<0.05) than for RPS11+/Mut. (b) Representative western blot of cleaved caspase 3, protein involved in apoptotic pathway during terminal erythroid differentiation in one RPS19-and one RPL11-mutated DBA patients compared with their controls

Back to article page